{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:23:54Z","timestamp":1774538634075,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI19C0481"],"award-info":[{"award-number":["HI19C0481"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to determine the risk of herpes zoster (HZ) in Korean rheumatoid arthritis (RA) patients on tofacitinib compared with tumor necrosis factor inhibitor (TNFi) treatment. From the prospective cohorts of RA patients who started tofacitinib or TNFi in an academic referral hospital in Korea, patients who started tofacitinib between March 2017 and May 2021 and those who started TNFi between July 2011 and May 2021 were included. Baseline characteristics of tofacitinib and TNFi users were balanced through inverse probability of treatment weighting (IPTW) using the propensity score including age, disease activity of RA and medication use. The incidence rate of HZ in each group and incidence rate ratio (IRR) were calculated. A total of 912 patients were included: 200 tofacitinib and 712 TNFi users. There were 20 cases of HZ among tofacitinib users and 36 among TNFi users during observation period of 331.4 person-years (PYs) and 1950.7 PYs, respectively. In IPTW analysis with a balanced sample, IRR of HZ was 8.33 (95% confidence interval 3.05\u201322.76). Tofacitinib use increased the risk of HZ compared with TNFi in Korean patients with RA, but the rate of serious HZ or permanent discontinuation of tofacitinib due to HZ event was low.<\/jats:p>","DOI":"10.1038\/s41598-023-33718-7","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:02:20Z","timestamp":1684170140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Increased risk of herpes zoster with tofacitinib treatment in Korean patients with rheumatoid arthritis: a single-center prospective study"],"prefix":"10.1038","volume":"13","author":[{"given":"Yeo-Jin","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Kyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyoungyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunwoo","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja-Young","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Jeong","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Bum","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Bum","family":"Jun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Hyun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8939","authenticated-orcid":false,"given":"Yoon-Kyoung","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"33718_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 17, 78 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"33718_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer, D. M. et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J. Inflamm. (Lond.) 7, 41 (2010).","journal-title":"J. Inflamm. (Lond.)"},{"key":"33718_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13075-022-02871-1","volume":"24","author":"S Jeong","year":"2022","unstructured":"Jeong, S. et al. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: A nationwide cohort study. Arthritis Res. Ther. 24, 180 (2022).","journal-title":"Arthritis Res. Ther."},{"key":"33718_CR4","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop, K. L. et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 66, 2675\u20132684 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"33718_CR5","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1128\/JVI.02592-07","volume":"82","author":"M Reichelt","year":"2008","unstructured":"Reichelt, M., Zerboni, L. & Arvin, A. M. Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J. Virol. 82, 3971\u20133983 (2008).","journal-title":"J. Virol."},{"key":"33718_CR6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/1756-185X.13300","volume":"21","author":"R Sakai","year":"2018","unstructured":"Sakai, R. et al. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: Epidemiological study using the Japanese health insurance database. Int. J. Rheum. Dis. 21, 1670\u20131677 (2018).","journal-title":"Int. J. Rheum. Dis."},{"key":"33718_CR7","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/art.23112","volume":"57","author":"AL Smitten","year":"2007","unstructured":"Smitten, A. L. et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 57, 1431\u20131438 (2007).","journal-title":"Arthritis Rheum."},{"key":"33718_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing, J., Gerhold, K. & Zink, A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52, 53\u201361 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"33718_CR9","doi-asserted-by":"publisher","first-page":"e001041","DOI":"10.1136\/rmdopen-2019-001041","volume":"5","author":"V Furer","year":"2019","unstructured":"Furer, V. et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): A systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 5, e001041 (2019).","journal-title":"RMD Open"},{"key":"33718_CR10","first-page":"962","volume":"30","author":"N Zhang","year":"2012","unstructured":"Zhang, N. et al. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. Clin. Exp. Rheumatol. 30, 962\u2013971 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"33718_CR11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/acr.21928","volume":"65","author":"BM Veetil","year":"2013","unstructured":"Veetil, B. M. et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: A population-based cohort study. Arthritis Care Res. (Hoboken) 65, 854\u2013861 (2013).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"33718_CR12","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1093\/rheumatology\/keab538","volume":"60","author":"J Qian","year":"2021","unstructured":"Qian, J. et al. Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults. Rheumatology (Oxford) 60, 5042\u20135051 (2021).","journal-title":"Rheumatology (Oxford)"},{"key":"33718_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","volume":"81","author":"I Redeker","year":"2022","unstructured":"Redeker, I. et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: Data from the German RABBIT register. Ann. Rheum. Dis. 81, 41\u201347 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"33718_CR14","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis, J. R. et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann. Rheum. Dis. 75, 1843\u20131847 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"33718_CR15","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1093\/rheumatology\/kez175","volume":"58","author":"G Almanzar","year":"2019","unstructured":"Almanzar, G. et al. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology (Oxford) 58, 2051\u20132060 (2019).","journal-title":"Rheumatology (Oxford)"},{"key":"33718_CR16","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop, K. L. et al. Herpes zoster and tofacitinib: Clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 69, 1960\u20131968 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"33718_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ijid.2007.08.002","volume":"12","author":"CI Kang","year":"2008","unstructured":"Kang, C. I. et al. Incidence of herpes zoster and seroprevalence of varicella-zoster virus in young adults of South Korea. Int. J. Infect. Dis. 12, 245\u2013247 (2008).","journal-title":"Int. J. Infect. Dis."},{"key":"33718_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jcv.2010.01.003","volume":"47","author":"WS Choi","year":"2010","unstructured":"Choi, W. S. et al. Disease burden of herpes zoster in Korea. J. Clin. Virol. 47, 325\u2013329 (2010).","journal-title":"J. Clin. Virol."},{"key":"33718_CR19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4078\/jrd.2020.27.3.182","volume":"27","author":"YB Seo","year":"2020","unstructured":"Seo, Y. B. et al. The practice guideline for vaccinating Korean patients with autoimmune inflammatory rheumatic disease. J. Rheum. Dis. 27, 182\u2013202 (2020).","journal-title":"J. Rheum. Dis."},{"key":"33718_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00296-011-2352-6","volume":"33","author":"SK Cho","year":"2013","unstructured":"Cho, S. K. et al. Factors influencing quality of life (QOL) for Korean patients with rheumatoid arthritis (RA). Rheumatol. Int. 33, 93\u2013102 (2013).","journal-title":"Rheumatol. Int."},{"key":"33718_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt, J. et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: Final results of a global, open-label, long-term extension study. Arthritis Res. Ther. 21, 89 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"33718_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer, J. M. et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol. 3, 173\u2013184 (2021).","journal-title":"ACR Open Rheumatol."},{"key":"33718_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg, S. R. et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).","journal-title":"N. Engl. J. Med."},{"key":"33718_CR24","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/1756-185X.13516","volume":"22","author":"EB Lee","year":"2019","unstructured":"Lee, E. B. et al. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data. Int. J. Rheum. Dis. 22, 1094\u20131106 (2019).","journal-title":"Int. J. Rheum. Dis."},{"key":"33718_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/art.41655","volume":"73","author":"N Bing","year":"2021","unstructured":"Bing, N. et al. Contribution of a European-prevalent variant near CD83 and an East Asian-prevalent variant near IL17RB to herpes zoster risk in tofacitinib treatment: Results of genome-wide association study meta-analyses. Arthritis Rheumatol. 73, 1155\u20131166 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"33718_CR26","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/acr.23769","volume":"71","author":"JR Curtis","year":"2019","unstructured":"Curtis, J. R. et al. Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids. Arthritis Care Res. (Hoboken) 71, 1249\u20131254 (2019).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"33718_CR27","doi-asserted-by":"publisher","first-page":"e001892","DOI":"10.1136\/rmdopen-2021-001892","volume":"8","author":"YJ Song","year":"2022","unstructured":"Song, Y. J. et al. Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: A nested case-control study. RMD Open 8, e001892 (2022).","journal-title":"RMD Open"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33718-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:03:46Z","timestamp":1684170226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33718-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33718"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33718-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"1 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YKS has received research grants from Bristol-Myers Squibb, Eisai, Pfizer, and JW Pharmaceutical. JYJ and HJY are employees and shareholders of Pfizer Inc. No potential conflicts of interest relevant to this article are reported. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7877"}}